CommercialPrior AuthHigh impact
08.01.62e, Nivolumab (Opdivo®), Nivolumab and Hyaluronidase-nvhy (Opdivo Qvantig™)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Mar 24, 2025
We identified it
Jun 19, 2026
Summary
Commercial insurance policy 08.01.62e for Nivolumab (Opdivo®) and Nivolumab and Hyaluronidase-nvhy (Opdivo Qvantig™) has been updated with changes to medical necessity criteria, coding requirements, and general guidelines. This affects billing and authorization requirements for these cancer immunotherapy drugs.
Action Required
By March 24, 2025: Billing team must review updated medical necessity criteria for Nivolumab (Opdivo®) and Nivolumab and Hyaluronidase-nvhy (Opdivo Qvantig™). Update prior authorization workflows and ensure documentation meets new requirements. Verify any coding changes in billing system. Access full policy details at the provided URL to implement specific changes.